Small-Vessel Vasculitis Studies

If you are interested in any of our research studies, please contact our research group at 215-614-4417 or email us at

Study Name

Medication Involved

Disease Studied

Currently Enrolling

Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non Severe, GPA (ABROGATE) YES GPA NO
The Assessment of Prednisone in Remission Trial (TAPIR) YES GPA NO
Benralizumab in eosinophilic granulomatosis with polyangiitis (EGPA) (MANDARA) YES EGPA NO
5506: The EGPA Registry NO EGPA YES
Nasal Microbiome in ANCA Associated Vasculitis and Relapsing Polychondritis (NMB) NO EGPA & RP YES 
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis (LoDoNaVasc) YES GPA, MPA, EGPA, GCA, Takayasu arteritis, PAN YES
One-Time DNA Study for Vasculitis (OTD) NO GPA, MPA, EGPA, GCA, Takayasu arteritis, PAN YES
Clinical Transcriptomics in Systemic Vasculitis (CUTIS) NO GPA, MPA, EGPA, PAN, IgAV, cryoglobulinemic, drug-induced, isolated cutaneous small vessel vasculitis, urticarial YES
Tissue Repository Collection Protocol NO GPA, MPA, EGPA, GCA, Takayasu's arteritis, PAN, cutaneous vasculitis YES
A Randomized Multicenter Study for Isolated Skin Vasculitis (ARAMIS) YES Cutaneous small/medium vessel vasculitis, cPAN, or IgA vasculitis YES
Depemokimab compared with mepolizumab for relapsing or refractory EGPA on standard of care therapy (OCEAN) YES EGPA YES
Obinutuzumab versus Rituximab in PR3-Patients with ANCA-Associated Vasculitis (PRRR) YES GPA/MPA YES